{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:55:39Z","timestamp":1779378939349,"version":"3.53.1"},"reference-count":62,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fujian Cancer Hospital Project","award":["2023YN11"],"award-info":[{"award-number":["2023YN11"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of polatuzumab vedotin\u2013rituximab\u2013cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The clinical outcomes were obtained from the POLARIX(\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03274492\">NCT03274492<\/jats:ext-link>\n                      ), SCHOLAR-1, ZUMA-7(\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03391466\">NCT03391466<\/jats:ext-link>\n                      ) and TRANSFORM(\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03575351\">NCT03575351<\/jats:ext-link>\n                      ) trials. Costs were derived from the Chinese official websites and published literature, and utility values were obtained from the published literature. The willingness-to-pay (WTP) threshold was set at triple the 2023 Chinese per capita gross domestic product of US$38 042.49\/quality-adjusted life year (QALY). Uncertainty was addressed using sensitivity analyses. The scenario analyses were also conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Chinese healthcare system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A hypothetical cohort of adult patients presenting with CD20-positive, patients with previously untreated DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Pola-R-CHP versus R-CHOP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The main outcomes of the study were QALYs, incremental cost-effectiveness ratio (ICER) and incremental net-health benefit (INHB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In China, the ICER and INHB of pola-R-CHP compared with R-CHOP were US$77 036.33\/QALY and \u22121.11 QALYs, respectively. The ICER was above the WTP threshold. Outcomes were most responsive to the price of pola. Probabilistic sensitivity analyses indicated that pola-R-CHP had a low probability of being cost-effective under the current WTP threshold. The scenario analyses demonstrated that when the price of pola fell by more than 32.5% to less than US$33.19\/mg, the economic probability of pola-R-CHP was greater than 50% in previously untreated CD20-positive patients with DLBCL in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pola-R-CHP is not cost-effective in the first-line treatment for previously untreated CD20-positive DLBCL in China. A value-based price for the cost of pola is less than US$33.19\/mg.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-086251","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:35:46Z","timestamp":1737408946000},"page":"e086251","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Is first-line treatment with polatuzumab vedotin\u2013rituximab\u2013cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03274492","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03391466","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575351","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03274492","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03391466","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575351","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1916-2357","authenticated-orcid":false,"given":"Liangliang","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanfu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xianyou County General Hospital, Putian, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuliang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-0523","authenticated-orcid":false,"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2025121511381284000_15.1.e086251.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025121511381284000_15.1.e086251.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"2025121511381284000_15.1.e086251.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"2025121511381284000_15.1.e086251.4","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(20)30222-2","article-title":"A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise","volume":"7","author":"Lue","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025121511381284000_15.1.e086251.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301077"},{"key":"2025121511381284000_15.1.e086251.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793984"},{"key":"2025121511381284000_15.1.e086251.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"2025121511381284000_15.1.e086251.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025121511381284000_15.1.e086251.9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025121511381284000_15.1.e086251.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"2025121511381284000_15.1.e086251.11","first-page":"1467","article-title":"Polatuzumab Vedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025121511381284000_15.1.e086251.12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The clinical development of antibody-drug conjugates - lessons from leukaemia","volume":"18","author":"Jabbour","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121511381284000_15.1.e086251.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"2025121511381284000_15.1.e086251.14","unstructured":"American Society of Hematology . 64th ASH\u2019Annual Meeting and Exposition.Available, 2022. Available: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Session23250.html [Accessed 14 Dec 2022]."},{"key":"2025121511381284000_15.1.e086251.15","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"2025121511381284000_15.1.e086251.16","unstructured":"National comprehensive cancer network\u00ae (nccn\u00ae). In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-Cell Lymphomasr. 2024."},{"key":"2025121511381284000_15.1.e086251.17","unstructured":"Guidelines of chinese society of clinical oncology \u00ae (csco\u00ae).lymphoid malignanciesr. 2024."},{"key":"2025121511381284000_15.1.e086251.18","unstructured":"National Medical Products Administration . Government service department, 2023. Available: https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20230113151759128.html [Accessed 13 Jan 2023]."},{"key":"2025121511381284000_15.1.e086251.19","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"2025121511381284000_15.1.e086251.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"2025121511381284000_15.1.e086251.21","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood.2022016624","article-title":"Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"key":"2025121511381284000_15.1.e086251.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"2025121511381284000_15.1.e086251.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2025121511381284000_15.1.e086251.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"2025121511381284000_15.1.e086251.25","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.1.1.37"},{"key":"2025121511381284000_15.1.e086251.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"2025121511381284000_15.1.e086251.27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1590\/S1020-49892002000800017","article-title":"Macroeconomics and health: investing in health for economic development","volume":"12","author":"Sachs","year":"2002","journal-title":"Rev Panam Salud Publica"},{"key":"2025121511381284000_15.1.e086251.28","unstructured":"National Bureau of Statistics, 2024. Available: https:\/\/data.stats.gov.cn\/ [Accessed 3 Mar 2024]."},{"key":"2025121511381284000_15.1.e086251.29","unstructured":"Guoen L , Shanlian H , Jiuhong W , et al . China Pharmacoeconomics Evaluation Guidelines. Beijing: China Market Press, 2020."},{"key":"2025121511381284000_15.1.e086251.30","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2025121511381284000_15.1.e086251.31","unstructured":"Yaozhi Data Service Provider . Drug information, 2024. Available: https:\/\/db.yaozh.com\/yaopinzhongbiao [Accessed 4 Oct 2024]."},{"key":"2025121511381284000_15.1.e086251.32","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.923619","article-title":"Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"key":"2025121511381284000_15.1.e086251.33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000671","article-title":"First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis","volume":"43","author":"Weng","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"2025121511381284000_15.1.e086251.34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","article-title":"Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China","volume":"127","author":"Gu","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"2025121511381284000_15.1.e086251.35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.996914","article-title":"Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025121511381284000_15.1.e086251.36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728440","article-title":"Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025121511381284000_15.1.e086251.37","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1002\/cam4.3121","article-title":"Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"key":"2025121511381284000_15.1.e086251.38","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.956792","article-title":"Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC","volume":"10","author":"Chen","year":"2022","journal-title":"Front Public Health"},{"key":"2025121511381284000_15.1.e086251.39","unstructured":"National Bureau of Statistics . Annual data. 2024. Available: https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01 [Accessed 3 Mar 2023]."},{"key":"2025121511381284000_15.1.e086251.40","unstructured":"US Department of Labor . Inflation & Prices Online Calculator: Bureau of Labor Statistics, 2024. Available: http:\/\/www.bls.gov\/cpi\/ [Accessed 1 Mar 2024]."},{"key":"2025121511381284000_15.1.e086251.41","unstructured":"Exchangerates 24.com . Exchange rate inquiry, 2024. Available: http:\/\/www.exchangerates24.com [Accessed 3 Mar 2024]."},{"key":"2025121511381284000_15.1.e086251.42","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1080\/10428194.2020.1808208","article-title":"Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"61","author":"Patel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2025121511381284000_15.1.e086251.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00438.x"},{"key":"2025121511381284000_15.1.e086251.44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/14737167.2020.1779063","article-title":"Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia","volume":"21","author":"Lasalvia","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025121511381284000_15.1.e086251.45","first-page":"953","article-title":"EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review","volume":"23","author":"Golicki","year":"2020","journal-title":"V H"},{"key":"2025121511381284000_15.1.e086251.46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3111\/13696998.2016.1151431","article-title":"A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada","volume":"19","author":"Beauchemin","year":"2016","journal-title":"J Med Econ"},{"key":"2025121511381284000_15.1.e086251.47","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40273-022-01169-z","article-title":"The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada","volume":"40","author":"Hillis","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"2025121511381284000_15.1.e086251.48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s41669-021-00316-0","article-title":"Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma","volume":"6","author":"Howell","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2025121511381284000_15.1.e086251.49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121511381284000_15.1.e086251.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"2025121511381284000_15.1.e086251.51","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials","volume":"29","author":"Maurer","year":"2018","journal-title":"Ann Oncol"},{"key":"2025121511381284000_15.1.e086251.52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2407","article-title":"Treatment of aggressive B-cell lymphomas","volume":"35 Suppl 1","author":"Smith","year":"2017","journal-title":"Hematol Oncol"},{"key":"2025121511381284000_15.1.e086251.53","unstructured":"2022 White Book on Survival of Patients with Diffuse Large B-Cell Lymphoma in China, 2023. Available: http:\/\/www.hongmiancf.org.cn\/NewsDetail\/3786928.html [Accessed 25 Feb 2024]."},{"key":"2025121511381284000_15.1.e086251.54","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1200\/JCO.22.00478","article-title":"Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and\/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma","volume":"41","author":"Vijenthira","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025121511381284000_15.1.e086251.55","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1080\/13696998.2023.2254640","article-title":"US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"26","author":"Matasar","year":"2023","journal-title":"J Med Econ"},{"key":"2025121511381284000_15.1.e086251.56","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjh.18869","article-title":"Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany","volume":"202","author":"Kambhampati","year":"2023","journal-title":"Br J Haematol"},{"key":"2025121511381284000_15.1.e086251.57","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/13696998.2023.2254162","article-title":"Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan","volume":"26","author":"Mizuoka","year":"2023","journal-title":"J Med Econ"},{"key":"2025121511381284000_15.1.e086251.58","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0406-6"},{"key":"2025121511381284000_15.1.e086251.59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.1401"},{"key":"2025121511381284000_15.1.e086251.60","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/cncr.30666","article-title":"Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives","volume":"123","author":"Wan","year":"2017","journal-title":"Cancer"},{"key":"2025121511381284000_15.1.e086251.61","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0073","article-title":"Cost\u2013effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma","volume":"12","author":"Ma","year":"2023","journal-title":"J Comp Eff Res"},{"key":"2025121511381284000_15.1.e086251.62","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40258-023-00817-5","article-title":"Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis","volume":"21","author":"Wu","year":"2023","journal-title":"Appl Health Econ Health Policy"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-086251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:38:22Z","timestamp":1765827502000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-086251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-086251"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-086251","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}